Rome, July 1 (AdnKronos Health) – What’s new in the world of pharmaceuticals. From the division of Baxter BioScience born today Baxalta Incorporated, a global biopharmaceutical group of 6 billion dollars, focused on innovative therapies for patients with rare diseases and disorders under-treated. The company announced it will strengthen its leadership in hematology and immunology, in addition to expanding the portfolio for oncology patients with limited treatment options. Baxalta has indeed in the pipeline to launch 20 new products by 2020, by leveraging the expertise of the management, on current production capacity and research presence in over 100 countries worldwide. From today Baxalta trades on the New York Stock Exchange under the ticker ‘BXLT’.
“The birth of Baxalta stems from a tradition of pioneering innovations and strategic partnerships, which places us in the best way to continue to develop innovative therapies. What characterizes us is our absolute focus on the needs of patients and the experience we have built step by step, “said Ludwig Hantson, chief executive officer and president of Baxalta Incorporated. “We are relying on research and development, internal and external, to develop new discoveries and to improve access to treatment and standards of care, working together with all our stakeholders: patients, professionals and policymakers.”
In the past pioneer with several innovations in the treatment of hemophilia and other bleeding disorders, the company was the first to make available for the plasma treatment. In the last two years Baxalta received 7 new approvals and currently has four products under scrutiny by regulators in the three areas of interest.
With more than 40 development programs worldwide, 13 of which are in the final stage, Baxalta aims to transform the way patients are treated hemophiliacs. Several acquisitions in the field of immunology and oncology, including the most recent, Merrimack and Sigma Tau, have strengthened the other strategic axes. The center of innovation, research and development is located in Cambridge, Massachusetts, and the headquarters is in Northern Illinois. Baxalta employs 16,000 employees worldwide.
In Italy there are two production plants, in Rieti and Pisa, and a branch office in Rome, with a total of about 500 employees. The plant in Rieti is a site of plasma fractionation, dedicated to the production of blood products, in the form of intermediates, such as immunoglobulins, albumin, and clotting factors. For volume of plasma treated and the high technological standards is considered among the best European production companies in the fractionation of blood products. In the establishment of Pisa it is instead concentrated the production of human albumin, subsequent to the splitting that is carried out in installations such as those of Rieti. Here you are completed stages of sterile filling and viral inactivation.
“The birth of Baxalta allows the entire organization an even greater focus on innovation and cutting-edge therapies for rare conditions in which we specialize,” said Fabio Andreola, as head of the Italian branch of Baxalta. Andreola has been in recent years at the head of the BioScience business unit of Baxter Italy. Economics graduate, has had previous professional experience in Italy and abroad in Johnson & amp; Johnson and Novo Nordisk. Baxalta In addition to leading the Italian subsidiary, will continue to lead the division Hematology.
No comments:
Post a Comment